Cure My Disease

Don't miss your cure!

 Log in / Sign up

A smarter way to track lung disease? new platform aims to personalize COPD and IPF care

NCT ID NCT07723638

Knowledge-focused Sponsor: Fondazione Don Carlo Gnocchi ETS Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This study is testing whether an integrated precision medicine platform can improve how doctors diagnose and manage chronic inflammatory lung diseases like COPD and idiopathic pulmonary fibrosis. Researchers will collect blood and saliva samples for biomarker analysis, monitor indoor and outdoor environmental exposures, and use telemedicine to track patients' health in real time. The goal is to see if combining these tools can lead to earlier detection of flare-ups, more personalized treatment, and better outcomes for the 200 adults enrolled.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Integrated precision medicine platform combining multi-omics biomarker profiling, environmental exposure assessment, telemedicine monitoring, and precision inhalation devices
What this could lead to
If successful, this approach could enable earlier and more accurate diagnosis of COPD and IPF, personalized treatment plans, and fewer disease flare-ups.
What could go wrong
This is an early-stage observational study, not a treatment trial. The new diagnostic tools may not prove more effective than current methods, and the results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Nov 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 18 years or older. * Diagnosis of chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), or combined pulmonary fibrosis and emphysema (CPFE), established according to current international diagnostic guidelines. * Ability and willingness to provide written informed consent. * Willingness to provide blood and saliva samples for biomarker analyses. * Willingness and ability to undergo clinical assessments and scheduled follow-up visits. * Willingness and ability to use study monitoring devices, including environmental monitoring devices and, where applicable, telemedicine tools. Exclusion Criteria: * Age younger than 18 years. * Inability or unwillingness to provide written informed consent. * Inability to comply with study procedures or scheduled follow-up. * Presence of any medical, psychiatric, or cognitive condition that, in the opinion of the investigator, would interfere with study participation or interpretation of the study results. * Participation in another interventional clinical trial that, in the opinion of the investigator, could interfere with the objectives of this study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic obstructive pulmonary disease (COPD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease combined pulmonary fibrosis-emphysema syndrome idiopathic pulmonary fibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic obstructive pulmonary disease (COPD) Idiopathic pulmonary fibrosis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.